CA2774669C - Oxaliplatin nanoparticles and method for preparing same - Google Patents

Oxaliplatin nanoparticles and method for preparing same Download PDF

Info

Publication number
CA2774669C
CA2774669C CA2774669A CA2774669A CA2774669C CA 2774669 C CA2774669 C CA 2774669C CA 2774669 A CA2774669 A CA 2774669A CA 2774669 A CA2774669 A CA 2774669A CA 2774669 C CA2774669 C CA 2774669C
Authority
CA
Canada
Prior art keywords
oxaliplatin
nanoparticle
mixture solution
lipid
solid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2774669A
Other languages
English (en)
French (fr)
Other versions
CA2774669A1 (en
Inventor
Sung Jae Lee
Young Hoon Kim
Sang Heon Lee
Kab Sig Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bio Synectics Inc
JW Pharmaceutical Corp
Original Assignee
Bio Synectics Inc
JW Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio Synectics Inc, JW Pharmaceutical Corp filed Critical Bio Synectics Inc
Publication of CA2774669A1 publication Critical patent/CA2774669A1/en
Application granted granted Critical
Publication of CA2774669C publication Critical patent/CA2774669C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/555Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10TTECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00Stock material or miscellaneous articles
    • Y10T428/29Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2774669A 2009-09-21 2010-09-20 Oxaliplatin nanoparticles and method for preparing same Expired - Fee Related CA2774669C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2009-0089079 2009-09-21
KR20090089079 2009-09-21
PCT/KR2010/006459 WO2011034394A2 (ko) 2009-09-21 2010-09-20 옥살리플라틴의 나노 입자 및 이를 제조하는 방법

Publications (2)

Publication Number Publication Date
CA2774669A1 CA2774669A1 (en) 2011-03-24
CA2774669C true CA2774669C (en) 2017-12-19

Family

ID=43759199

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2774669A Expired - Fee Related CA2774669C (en) 2009-09-21 2010-09-20 Oxaliplatin nanoparticles and method for preparing same

Country Status (11)

Country Link
US (1) US9393201B2 (https=)
EP (1) EP2481396A4 (https=)
JP (1) JP5759464B2 (https=)
KR (1) KR101396461B1 (https=)
CN (1) CN102665689B (https=)
AU (1) AU2010296180B2 (https=)
CA (1) CA2774669C (https=)
IN (1) IN2012DN02576A (https=)
MX (1) MX348668B (https=)
RU (1) RU2563997C2 (https=)
WO (1) WO2011034394A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2983490A1 (en) * 2013-03-15 2016-02-17 DSM IP Assets B.V. Solid lipid nanoparticles (ii)
AU2018255063A1 (en) * 2017-04-21 2018-11-22 Bio-Synectics Inc. Method for preparing active material nanoparticles using lipid as lubricant for milling
KR101895237B1 (ko) * 2017-06-12 2018-09-07 목포대학교산학협력단 옥살리플라틴을 포함하는 경구용 약물전달 조성물 및 이의 제조방법
KR102184117B1 (ko) * 2017-10-31 2020-11-30 주식회사 삼양바이오팜 수용해도 및 생체이용율이 개선된 소라페닙 나노입자 경구용 조성물 및 이의 제조 방법
ES2927608T3 (es) 2018-09-14 2022-11-08 Inst Nat Sante Rech Med Sistema de liberación de fármacos para fármacos basados en platino
CN110917345B (zh) * 2019-09-26 2021-11-09 苏州百迈生物医药有限公司 一种化疗免疫组合药物及其制备方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2989695A (en) * 1994-08-08 2000-03-07 Debiopharm S.A. Pharmaceutically stable oxaliplatinum preparation
FR2740686B1 (fr) 1995-11-03 1998-01-16 Sanofi Sa Formulation pharmaceutique lyophilisee stable
CN1191067C (zh) * 1997-02-05 2005-03-02 法玛西雅厄普约翰美国公司 高不溶性铂配合物的脂质复合物和脂质体
GB9804013D0 (en) 1998-02-25 1998-04-22 Sanofi Sa Formulations
US7217735B1 (en) * 1999-04-09 2007-05-15 Au Jessie L-S Methods and compositions for enhancing delivery of therapeutic agents to tissues
JP2003524624A (ja) * 1999-04-09 2003-08-19 ジェシー エル エス オウ 治療薬の組織への送達を高める方法及び組成物
WO2002047725A2 (fr) 2000-12-12 2002-06-20 Debiopharm S.A. Preparation pharmaceutique d'oxaliplatine pour administration par voie parenterale et procede d'obtention de ladite preparation
US6476068B1 (en) * 2001-12-06 2002-11-05 Pharmacia Italia, S.P.A. Platinum derivative pharmaceutical formulations
US20050142205A1 (en) * 2003-07-18 2005-06-30 Julia Rashba-Step Methods for encapsulating small spherical particles prepared by controlled phase separation
CN101703467A (zh) 2003-08-28 2010-05-12 梅恩医药有限公司 含有酸的奥沙利铂制剂
KR100603974B1 (ko) 2003-12-05 2006-07-25 김갑식 고체상 지질을 용매로 이용한 나노수준의 또는 비결정질입자의 제조 방법
CN1775216A (zh) * 2004-11-15 2006-05-24 胡才忠 一种新型的制剂——奥沙利铂脂质体
DE102005011786A1 (de) * 2005-03-11 2006-09-14 Pharmasol Gmbh Verfahren zur Herstellung ultrafeiner Submicron-Suspensionen
BRPI0617663A2 (pt) * 2005-10-21 2011-08-02 Panacea Biotec Ltd composições aperfeiçoadas para terapia de cáncer
KR20070067768A (ko) 2005-12-23 2007-06-29 주식회사 삼양사 안정한 옥살리플라틴 조성물 및 이의 제조방법
GR20060100144A (el) * 2006-03-03 2007-10-17 Θεραπεια του καρκινου με χρηση οξαλιπλατινης εγκλεισμενης μεσα σε λιποσωματα και απο κοινου εγκλεισμος στο λιποσωμιακο μοριο περισσοτερων απο ενος φαρμακευτικου παρασκευασματος h gene
KR101342119B1 (ko) 2006-05-04 2013-12-18 (주)바이오시네틱스 디올 화합물을 이용한 나노수준의 활성물질 입자 제조 방법
JP4830019B2 (ja) * 2006-05-04 2011-12-07 バイオ−シネクティクス インク. ナノスケールの活物質粒子の製造方法
CN1868455A (zh) * 2006-05-20 2006-11-29 沈阳药科大学 奥沙利铂磷脂复合物静脉给药的纳米混悬注射剂
KR100913063B1 (ko) 2006-09-13 2009-08-21 주식회사유한양행 옥살리플라틴-함유 주사용 용액
JP2010515493A (ja) * 2007-01-12 2010-05-13 ヤンファン リー, X線不透過性生物分解微小球型血管栓塞材料
CN100563646C (zh) * 2007-07-13 2009-12-02 陈祥峰 一种奥沙利铂脂质体葡萄糖制剂的制备方法
US20100310661A1 (en) * 2007-07-16 2010-12-09 Poniard Pharmaceuticals, Inc. Oral formulations for picoplatin

Also Published As

Publication number Publication date
AU2010296180A1 (en) 2012-04-19
JP5759464B2 (ja) 2015-08-05
RU2563997C2 (ru) 2015-09-27
US9393201B2 (en) 2016-07-19
CN102665689B (zh) 2015-04-22
AU2010296180B2 (en) 2016-05-05
WO2011034394A3 (ko) 2011-11-03
WO2011034394A2 (ko) 2011-03-24
MX2012003393A (es) 2012-07-25
JP2013505291A (ja) 2013-02-14
EP2481396A4 (en) 2014-03-05
EP2481396A2 (en) 2012-08-01
US20120177728A1 (en) 2012-07-12
CA2774669A1 (en) 2011-03-24
KR101396461B1 (ko) 2014-05-20
KR20120046243A (ko) 2012-05-09
CN102665689A (zh) 2012-09-12
RU2012116085A (ru) 2013-10-27
IN2012DN02576A (https=) 2015-08-28
MX348668B (es) 2017-06-23

Similar Documents

Publication Publication Date Title
CN102056596B (zh) 纳米颗粒制剂及其用途
CA2774669C (en) Oxaliplatin nanoparticles and method for preparing same
Zhao et al. Preparation and cytotoxic activity of hydroxycamptothecin nanosuspensions
JP2010533714A5 (https=)
TW200904483A (en) Proliposomal and liposomal compositions of poorly water soluble drugs
CN102458112A (zh) 纳米颗粒制剂及其用途
KR20220112737A (ko) 리바스티그민을 포함하는 장기지속형 제제 및 이의 제조방법
KR20110056042A (ko) 종양세포 표적지향을 위한 나노 입자 및 이의 제조방법
CN102048725A (zh) 紫杉醇胆固醇复合物
JP2022160584A (ja) オキサリプラチンを含む経口用薬物送達組成物及びその製造方法
Han et al. A new approach to produce drug nanosuspensions CO2-assisted effervescence to produce drug nanosuspensions
CN102357075A (zh) 一种多西他赛纳米制剂及其制备方法
AU2006257428B2 (en) Oral solid pharmaceutical formulation of the tubulin inhibitor indibulin
CN105919935A (zh) 索拉非尼药物脂质纳米混悬剂及其制备方法
US12370187B2 (en) Composition containing antitumor drug, and preparation method thereof and use thereof
CN102772369A (zh) 一种多烯紫杉醇长循环纳米粒制剂及其制备方法
CN110759928A (zh) 利用可逆分解法制备喜树碱类药物纳米晶体
CN101708158A (zh) 毛萼乙素纳米混悬剂及其制备方法

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150722

MKLA Lapsed

Effective date: 20220322

MKLA Lapsed

Effective date: 20200921